Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 301

Related Citations for PubMed (Select 19707743)

1.

Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes.

Sayyed SG, Hägele H, Kulkarni OP, Endlich K, Segerer S, Eulberg D, Klussmann S, Anders HJ.

Diabetologia. 2009 Nov;52(11):2445-54. doi: 10.1007/s00125-009-1493-6. Epub 2009 Aug 26.

PMID:
19707743
2.

Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease.

Darisipudi MN, Kulkarni OP, Sayyed SG, Ryu M, Migliorini A, Sagrinati C, Parente E, Vater A, Eulberg D, Klussmann S, Romagnani P, Anders HJ.

Am J Pathol. 2011 Jul;179(1):116-24. doi: 10.1016/j.ajpath.2011.03.004. Epub 2011 Apr 30.

3.
4.

Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease.

Menini S, Iacobini C, Oddi G, Ricci C, Simonelli P, Fallucca S, Grattarola M, Pugliese F, Pesce C, Pugliese G.

Diabetologia. 2007 Dec;50(12):2591-9. Epub 2007 Sep 28.

PMID:
17901943
5.

Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis.

Herbach N, Schairer I, Blutke A, Kautz S, Siebert A, Göke B, Wolf E, Wanke R.

Am J Physiol Renal Physiol. 2009 Apr;296(4):F819-29. doi: 10.1152/ajprenal.90665.2008. Epub 2009 Feb 11.

6.

Systemic and renal growth hormone-IGF1 axis involvement in a mouse model of type 2 diabetes.

Segev Y, Eshet R, Yakir O, Haim N, Phillip M, Landau D.

Diabetologia. 2007 Jun;50(6):1327-34. Epub 2007 Apr 19.

PMID:
17443310
7.

Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms.

Baba M, Wada J, Eguchi J, Hashimoto I, Okada T, Yasuhara A, Shikata K, Kanwar YS, Makino H.

J Am Soc Nephrol. 2005 Nov;16(11):3222-34. Epub 2005 Sep 21.

8.

Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10.

Sayyed SG, Gaikwad AB, Lichtnekert J, Kulkarni O, Eulberg D, Klussmann S, Tikoo K, Anders HJ.

Nephrol Dial Transplant. 2010 Jun;25(6):1811-7. doi: 10.1093/ndt/gfp730. Epub 2010 Jan 12.

9.

p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.

Wolf G, Schanze A, Stahl RA, Shankland SJ, Amann K.

Kidney Int. 2005 Oct;68(4):1583-9.

PMID:
16164635
10.

Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice.

Lim AK, Ma FY, Nikolic-Paterson DJ, Thomas MC, Hurst LA, Tesch GH.

Diabetologia. 2009 Aug;52(8):1669-79. doi: 10.1007/s00125-009-1399-3. Epub 2009 May 23.

PMID:
19466391
11.

Lack of {alpha}8-integrin aggravates podocyte injury in experimental diabetic nephropathy.

Hartner A, Cordasic N, Menendez-Castro C, Volkert G, Yabu JM, Kupraszewicz-Hutzler M, Rascher W, Hilgers KF.

Am J Physiol Renal Physiol. 2010 Nov;299(5):F1151-7. doi: 10.1152/ajprenal.00058.2010. Epub 2010 Sep 8.

12.

Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice.

Chow FY, Nikolic-Paterson DJ, Ma FY, Ozols E, Rollins BJ, Tesch GH.

Diabetologia. 2007 Feb;50(2):471-80. Epub 2006 Dec 12.

PMID:
17160673
13.

Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats.

Hoshi S, Shu Y, Yoshida F, Inagaki T, Sonoda J, Watanabe T, Nomoto K, Nagata M.

Lab Invest. 2002 Jan;82(1):25-35.

PMID:
11796823
14.

Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy.

Ziyadeh FN, Wolf G.

Curr Diabetes Rev. 2008 Feb;4(1):39-45. Review.

PMID:
18220694
15.

Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.

Deb DK, Sun T, Wong KE, Zhang Z, Ning G, Zhang Y, Kong J, Shi H, Chang A, Li YC.

Kidney Int. 2010 Jun;77(11):1000-9. doi: 10.1038/ki.2010.22. Epub 2010 Feb 24.

PMID:
20182412
16.

ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.

Gross ML, El-Shakmak A, Szábó A, Koch A, Kuhlmann A, Münter K, Ritz E, Amann K.

Diabetologia. 2003 Jun;46(6):856-68. Epub 2003 Jun 11.

PMID:
12802493
17.
18.

Effects of sulfonylureas, alpha-endosulfine counterparts, on glomerulosclerosis in type 1 and type 2 models of diabetes.

Biederman JI, Vera E, Rankhaniya R, Hassett C, Giannico G, Yee J, Cortes P.

Kidney Int. 2005 Feb;67(2):554-65. Erratum in: Kidney Int. 2005 Mar;67(3):1213.

PMID:
15673303
19.

An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes.

Sayyed SG, Ryu M, Kulkarni OP, Schmid H, Lichtnekert J, Grüner S, Green L, Mattei P, Hartmann G, Anders HJ.

Kidney Int. 2011 Jul;80(1):68-78. doi: 10.1038/ki.2011.102. Epub 2011 Apr 20.

PMID:
21508925
20.

Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone.

Makino H, Miyamoto Y, Sawai K, Mori K, Mukoyama M, Nakao K, Yoshimasa Y, Suga S.

Diabetes. 2006 Oct;55(10):2747-56.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk